Lavaca Capital’s Pfizer PFE Stock Holding History

Lavaca Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,000	Closed	-$326K	–	172
2021 Q1	$326K	Buy	+9,000	New	+$320K	0.03%	107

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Lavaca Capital's PFE Position: Q2 2026 in Review

Lavaca Capital reduced its Pfizer (PFE) stake by 3.5% in Q2 2026, selling an estimated $10.3K and leaving 10,873 shares worth $262K. The position accounts for 0.03% of the portfolio, ranked #113.

Lavaca Capital first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.44M in Q1 2021. 2,834 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Lavaca Capital held 10,873 shares of Pfizer worth $262K as of Q2 2026.
Lavaca Capital sold 394 Pfizer shares in Q2 2026, an estimated $10.3K.
Pfizer made up 0.03% of Lavaca Capital's portfolio in Q2 2026, its #113 holding.
Lavaca Capital first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
Lavaca Capital's Pfizer position peaked at $2.44M in Q1 2021.
2,834 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Lavaca Capital's 13F filing for Q2 2026, filed 14 Aug 2026.